As medications become increasingly popular to support weight loss, not all of them are approved by the U.S. Food and Drug ...

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on NVO.

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

Viking Therapeutics became famous in the biotech world last year after announcing positive phase 2 results for VK2735, an investigational GLP-1 weight loss candidate. The stock has not performed well ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

President Donald Trump's executive order directs pharmaceutical companies to lower their prices to levels closer to those ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

The best metric is not weight, but a particularly toxic kind of fat.

For the first time, scientists have pitted the two most popular weight loss drugs against each other in a direct competition ...